Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) FCF Margin (2019 - 2025)

Keros Therapeutics filings provide 6 years of FCF Margin readings, the most recent being 4485.27% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1359885.0% to 4485.27% in Q4 2025 year-over-year; TTM through Dec 2025 was 44.01%, a 13562265.0% decrease, with the full-year FY2025 number at 44.05%, changed N/A from a year prior.
  • FCF Margin hit 4485.27% in Q4 2025 for Keros Therapeutics, down from 12.94% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 9113.58% in Q4 2024 to a low of 408362.5% in Q3 2023.
  • Median FCF Margin over the past 5 years was 160.02% (2025), compared with a mean of 40793.06%.
  • Biggest five-year swings in FCF Margin: surged 40010013bps in 2024 and later crashed -1359885bps in 2025.
  • Keros Therapeutics' FCF Margin stood at 110.19% in 2021, then surged by 92bps to 8.41% in 2022, then crashed by -216048bps to 18180.42% in 2023, then soared by 150bps to 9113.58% in 2024, then crashed by -149bps to 4485.27% in 2025.
  • The last three reported values for FCF Margin were 4485.27% (Q4 2025), 12.94% (Q3 2025), and 160.02% (Q2 2025) per Business Quant data.